Olema Oncology (OLMA) Jefferies Global Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference 2026 summary
3 Jun, 2026Key clinical program updates
Phase I dose escalation for OP-3136 showed encouraging single-agent activity in ER-positive, HER2-negative breast cancer and castration-resistant prostate cancer, with lower and less severe cytopenias compared to competitors.
No dose-limiting toxicities observed up to 60 mg daily; dose selection will consider both PK/PD data and combination activity, with key combination data expected by end of this year or early next.
Combination studies with fulvestrant and palazestrant are ongoing, aiming to improve efficacy and patient quality of life with oral regimens.
Collaboration with Bayer to combine OP-3136 with Nubeqa in prostate cancer will begin soon.
Industry context and competitive landscape
Recent ASCO and persevERA data highlight the evolving standard of care in breast cancer, with palazestrant showing superior efficacy and combinability compared to other estrogen receptor agents.
PersevERA trial, despite not meeting statistical significance, demonstrated a clinically meaningful PFS benefit, informing potential design changes for OPERA-02.
Market opportunities in breast cancer are significant, with first-line settings exceeding $10 billion annually and additional potential in second/third-line and prostate cancer.
Forward-looking statements and trial design
OPERA-02 trial design may be revised based on persevERA and upcoming SERENA-4 data, particularly regarding control arm performance and patient enrollment.
OPERA-01, targeting second/third-line settings, is expected to read out in the fall, with hopes of demonstrating benefit in both ESR1 mutant and wild-type populations.
Moving into the adjuvant setting is a strategic priority but contingent on capital and potential partnerships due to high trial costs.
Company maintains strong cash position, with runway into the second half of 2028, excluding costs for a large adjuvant trial.
Latest events from Olema Oncology
- Q1 OPERA-01 data will shape a potential mid-2028 launch and broader treatment opportunity.OLMA
Stifel 2026 Healthcare Conference 2026 - OPERA-01 data in Q1 2027 will test palazestrant across both ESR1 subsets.OLMA
3rd Annual Guggenheim Healthcare Innovation Conference - Clinical spending deepened losses, while cash runway is projected through mid-2028.OLMA
Q3 2026 - Phase III breast cancer trial readout for palazestrant expected Q1 2027; new combo data due next year.OLMA
H.C. Wainwright 28th Annual Global Investment Conference - Palazestrant and KAT6 programs offer strong differentiation and major market potential, with key data ahead.OLMA
Morgan Stanley 24th Annual Global Healthcare Conference - Phase III breast cancer trials for palazestrant target major markets, with key data due in Q1 2027.OLMA
Citigroup’s Biopharma Back to School Summit 2026 - Net loss rose 44% to $63.2M in Q2 2026 as Phase 3 trial enrollment completed and cash reached $461M.OLMA
Q2 2026 - Pivotal trials and new combinations position the pipeline for major advances in breast cancer care.OLMA
Jefferies London Healthcare Conference 2025 - Phase III breast cancer data expected in fall; KAT6 combos and strong cash position support growth.OLMA
Goldman Sachs 47th Annual Global Healthcare Conference 2026